SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community actively champions the "OG meme" narrative of Rage Comics, viewing it as the foundational "meme reset." This dedicated base is passionately building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and widespread recognition as they aim to lead the next major meme coin cycle.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing high trading volume driven by news of a strategic manufacturing partnership to scale production of its fingerprinting drug screening reader. This announcement has ignited a fierce debate within the trading community, with many anticipating a short squeeze due to the stock's low float, while others express caution regarding potential dilution and pump-and-dump dynamics.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Federal reclassification of cannabis and the elimination of the 280E tax barrier are driving significant attention to Weedcoin, as the community positions it as a key beneficiary of these policy changes on Solana. Enthusiasts are rallying around its 

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF is generating significant buzz as investors grapple with its perceived disconnection from the underlying asset. Intense community discussions center on the impact of distributions and the inherent decay of this leveraged product, leading to a polarized debate over its immediate trajectory and risk profile.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is seeing significant community discussion driven by the departure of its CFO, which has sparked diverse speculation about a potential acquisition, alongside a new expanded access agreement for its rare disease treatment, MIPLYFFA, to broaden global reach. Simultaneously, investors are closely watching the ongoing legal proceedings with Commave, with varying interpretations of recent court developments influencing sentiment around the future of its KP1077 asset.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high December and fourth-quarter 2025 vehicle deliveries, meeting the high end of its guidance and nearing one million cumulative vehicles overall. This strong performance, coupled with China's extended EV purchase tax benefits favoring battery-swapping models, has ignited community discussions about potential Q4 profitability and a bright 2026 outlook for the multi-brand EV maker. Many investors are optimistic, comparing NIO's sales favorably against peers and anticipating significant upside despite recent price volatility.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending significantly following the FDA's Complete Response Letter to competitor Corcept Therapeutics for its Cushing's syndrome treatment. This outcome is widely viewed by the community and analysts as a "massive tailwind" for Xeris's Recorlev, strengthening its market position in a growing multi-billion dollar sector. Investors are actively discussing this enhanced competitive moat and the promising future of its XP-8121 pipeline.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending amid recent regulatory approvals for a key acquisition and an analyst firm initiating coverage with an "Overweight" rating. While some investors voice frustration over past delays in commercial revenue and management communication, a significant portion of the community maintains strong conviction in the long-term potential of its specialized isotope technology for critical sectors including advanced energy, medical applications, and next-generation computing. The conversation highlights a divide between those concerned about execution timelines and those focused on strategic asset accumulation and the company's unique market position.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending after definitively agreeing to sell Bressner Technology for $22.4M, a strategic move the community views as a profitable pivot to focus on high-growth AI and edge computing. This substantial cash infusion and sharpened corporate focus are fueling strong anticipation for impending large military contracts, particularly a potential $200M situational awareness system. Investors are actively discussing the company's low float and undervalued status, anticipating significant upside as the AI and defense narrative gains wider recognition.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending amid intense community debate surrounding mixed interim Phase 2 data for its cystic fibrosis therapy, ARCT-032, where positive mucus plug reduction signals are being weighed against limited lung function improvement. Concurrently, investors are closely following a high-stakes trade secret lawsuit against AbbVie, which many believe could lead to a significant settlement or buyout, fueling conversations about the stock's perceived undervaluation and potential for a substantial short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood shells out $1.3 million on biotech stock

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics (NTLA), scooping up 145,153 shares in the gene-editing play. For the most part, it...

Caribou Biosciences (NASDAQ:CRBU) Trading Up 2.4% - Should You Buy?

Caribou Biosciences (NASDAQ:CRBU) Trading 2.4% Higher - Here's Why...

Caribou Biosciences Target of Unusually Large Options Trading (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) was the recipient of some unusual options trading on Monday. Investors purchased 2,867 call options on the stock. This represents an increase...

Caribou Biosciences, Inc. $CRBU Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 626.8% in the 2nd quarter, according to its most recent Form 13F filing with the...

Caribou Biosciences (NASDAQ:CRBU) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus...

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -147.37% and -71.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Brookline Capital Management Predicts CRBU FY2026 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Analysts at Brookline Capital Management dropped their FY2026 earnings per share (EPS) estimates for Caribou Biosciences in a research note...

<p>Shares of Caribou Biosciences, Inc. (CRBU) jumped 52% in the pre-market session on Monday after the company announced positive data from early-stage trials of two of its CAR-T cell therapies.</p><p>While one of the therapies was evaluated for the treatment of multiple myeloma, a blood cancer of plasma cells, the other was assessed in B-cell non-Hodgkin lymphoma (NHL), a cancer that originates in B lymphocytes, a type of white blood cell that fights infection.</p><h2 class="st-heading-2">Study In Multiple Myeloma</h2><p>The company said that the first clinical data for its CB-011 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179047/0/en/Caribou-Biosciences-Announces-Positive-Data-from-CaMMouflage-Phase-1-Trial-of-CB-011-in-Multiple-Myeloma.html">highlights</a> its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.</p><p>The company now expects to advance the program into the dose expansion phase by the end of the year. In the dose escalation portion of the trial, CB-011 had a manageable safety profile across all dose levels, the company noted. The portion of the trial evaluated the safety and efficacy of CB-011 in 48 patients at multiple dose levels and following two different chemotherapy treatments.</p><h2 class="st-heading-2">Study In B-cell non-Hodgkin lymphoma</h2><p>Meanwhile, data from an early-stage trial of vispacabtagene regedleucel (Vispa-cel) demonstrated the efficacy and durability of the cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179104/0/en/Caribou-Biosciences-Announces-Positive-Data-from-ANTLER-Phase-1-Trial-Demonstrating-Efficacy-and-Durability-of-Vispa-cel-CB-010-an-Allogeneic-CAR-T-Cell-Therapy-on-Par-with-Autolog.html">said</a>. Vispa-cel was generally well-tolerated, allowing for administration in the outpatient setting, the company added.</p><p>“We believe that with these results, Caribou has achieved what the field has long sought — strong evidence that an allogeneic CAR-T cell therapy can be on par with the efficacy and durability of autologous treatments and broaden access with a safety profile that allows for outpatient use,” said CEO Rachel Haurwitz.</p><p>Allogeneic CAR-T cell therapy is a type of "off-the-shelf" cancer treatment that uses T-cells from a healthy donor, rather than the patient's own cells, allowing immediate availability. Autologous therapy, however, uses a patient's own cells or tissues, which are collected, processed outside the body, and then reintroduced to the same individual.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRBU">CRBU stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.</p><p>CRBU stock is up 52% this year and approximately 3% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-sales-in-us-rise-1.6-percent-in-october/cL2NX8OR3CR">Ford Sales In US Rise 1.6% In October On Continued Truck Demand</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Rising stock market chart on a trading board background.

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For  Cancer Treatments

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 

Equity

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 


Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates

Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

CRBU
Caribou Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRBU News

CRBUCaribou Biosciences Inc